Trevi Therapeutics (TRVI) Total Liabilities (2018 - 2026)

Trevi Therapeutics has reported Total Liabilities for 9 years, with the latest figure at $7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 0.9% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (down 0.9% YoY), and the FY2025 full-year result was $10.2 million, down 9.43% from the prior year.
• Total Liabilities for Q1 2026 stood at $7.5 million, down from $10.2 million in the prior quarter.
• The five-year high for Total Liabilities was $20.9 million in Q2 2022, with the low at $5.9 million in Q2 2023.
• Average Total Liabilities over 5 years is $11.1 million, with a median of $9.8 million recorded in 2025.
• Year-over-year, Total Liabilities slumped 71.75% in 2023 and soared 64.18% in 2024.
• Tracing TRVI's Total Liabilities over 5 years: stood at $15.6 million in 2022, then slumped by 55.93% to $6.9 million in 2023, then soared by 64.18% to $11.3 million in 2024, then retreated by 9.43% to $10.2 million in 2025, then declined by 26.64% to $7.5 million in 2026.
• The last three Total Liabilities figures came in at $7.5 million (Q1 2026), $10.2 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.

Peer Comparison